| Identification | Back Directory | [Name]
Indatuximab Ravtansine | [CAS]
1238517-16-2 | [Synonyms]
Indatuximab Ravtansine
Research Grade Indatuximab (DHD30801) |
| Hazard Information | Back Directory | [Uses]
Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1]. | [in vivo]
Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival[1]. | Animal Model: | SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1] | | Dosage: | 5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg | | Administration: | i.v.; once | | Result: | Inhibited multiple myeloma tumour growth in vivo and improved host survival. |
| [References]
[1] Kurt Sch?nfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13. DOI:10.1186/s13045-016-0380-0 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|